Digital Health and Wellness: 7 Early Warning Signs Your Digital

By: Tiago Santana - Founder & CEO, Gray Group International • Serial entrepreneur and growth strategist who has built and scaled multiple companies across technology, media, and consulting. Expert in growth strategist and editorial voice for a global think tank building companies that advance the human experience

Key takeaways

• Start with a thorough assessment of your specific requirements before choosing a solution.
• Compare multiple options and verify that each meets your documented criteria.
• Avoid over- or under-investing: the right fit balances cost, performance, and long-term value.

In digital health and wellness, the hardest problems are often not technical. They are about fit. A product can look strong in a demo and still fail once buyers ask about claims, data, workflow, and proof. That is why early warning signs matter. They help teams spot when a wellness app is drifting into regulated territory, when a provider tool.

In This Article:

• Key takeaways
• What digital health and wellness really includes
• Early warning signs your strategy is off
• Are trust and compliance at risk?
• How evidence and adoption break down
• What to do next

What digital health and wellness really includes

In short: Digital health and wellness covers a wide range of products.

Digital health and wellness covers a wide range of products. Some are consumer apps for meditation, sleep, or fitness. Others support telehealth, remote patient monitoring, care coordination, or digital therapeutics. Many tools also move data between systems, which adds another layer of risk and value. The label may be broad, but the business rules are not.

That difference matters because each category has its own buyers, proof needs, and compliance burden. A consumer wellness app may live or die on engagement. A provider tool may be judged on workflow fit. A regulated product may need stronger clinical evidence and security controls. The sooner a team sees which lane it is in, the fewer surprises it faces later.

When a wellness app starts making medical claims

A small wording change can shift a product's risk level fast. Saying an app helps users relax is very different from saying it treats anxiety or reduces depression symptoms. The first is usually viewed as general wellness. The second can trigger medical device questions, evidence demands, and legal review. Marketing teams often move faster than clinical or regulatory teams, and that is where trouble starts.

This is one of the clearest early warning signs. If your copy sounds stronger than your proof, buyers will notice. They may ask for study design, safety review, or intended use language before they move forward. That does not always mean the product is wrong. It means the claims have outgrown the current evidence.

Why wearables and telehealth are not one market

Wearables and telehealth are both part of digital health, but they do not behave the same way. A fitness tracker may serve consumers directly, while a telehealth platform may need to fit into employer plans or health system workflows. Even when the user experience looks simple, the economics behind the product can be very different.

This is why broad category thinking can mislead teams. A wearable that tracks steps is not the same as a device that supports clinical monitoring. A video visit tool is not the same as a care coordination platform with prescribing and follow-up. The deeper the product reaches into care, the more it must match the needs of clinicians, payers, and administrators.

Early warning signs your strategy is off

In short: The strongest warning sign is not poor design.

The strongest warning sign is not poor design. It is mismatch. Many digital health teams build a product for one problem and later discover that the buyer is screening for a different one. The user may like the app, but the organization may care more about compliance, evidence, integration, or reimbursement. When that happens, momentum slows.

Another sign is weak sequencing. Some teams spend months polishing features before checking whether the market will accept the product in its current form. In health care, this can waste time and money. The roadmap should follow the buying reality, not the other way around.

Do remote patient monitoring goals lack focus?

Remote patient monitoring works best when it starts narrow. One condition set, one care pathway, and one clear economic owner are easier to prove than a broad platform claim. If a team tries to cover too many use cases too early, it can create more work for care teams than value. That often leads to slow adoption or pilot fatigue.

A focused RPM plan also makes staffing clearer. Someone must review alerts, decide what matters, and act on it. If that role is not designed early, the product may look useful but still fail in practice. Good RPM is not just about collecting data. It is about turning that data into the right action at the right time.

Are buying cycles longer than planned?

If deals take much longer than expected, the buyer may be asking for more proof than your team prepared. Health care sales often include legal review, security review, clinical review, IT review, and budget approval. That is normal. What is not normal is assuming the process will move like standard SaaS.

Long cycles are not always a bad sign. Sometimes they mean the buyer is serious and just needs the right materials. But if you do not have security docs, workflow maps, and evidence packets ready early, the process stalls. In digital health, trust assets are part of the sales motion.

Is care coordination harder than your roadmap assumed?

Care coordination sounds simple until it touches real systems. Data may need to move between EHRs, labs, messages, patients, and caregivers. Each step can create delay. Each handoff can create a new approval need. What seemed like a feature often becomes a full integration project.

This is where many teams miss the scale of the task. Interoperability is not a nice extra. It is part of the product's delivery model. If your tool needs to fit into existing workflows, that fit must be designed early. Otherwise, even a good product can become one more dashboard no one wants to open.

Are trust and compliance at risk?

In short: Trust problems usually show up before users can explain them.

Trust problems usually show up before users can explain them. In health, people ask silent questions fast. Will this help me? Will this expose me? Will this waste my time? If your product raises doubt on any of those points, growth will slow, even if the feature set is strong.

Compliance and trust also affect enterprise buying. A hospital or payer may like the concept but still block the deal if security, privacy, or data handling looks weak. In this market, trust is not branding. It is part of the product.

Is health data security weaker than users expect?

Many teams assume standard cloud security is enough. It is not always enough for health-related data. Symptom logs, biometrics, therapy notes, and medication details all need careful handling. Access control, consent language, and data use policies should be clear and easy to review.

Another common mistake is hiding important terms in dense privacy text. Users rarely read it closely, and buyers often do. If your product touches sensitive data, the safer path is plain language and strong controls from the start. That helps both adoption and procurement.

Can interoperability gaps block partner adoption?

Yes. A partner may like your product and still refuse it if it does not fit their systems. FHIR support can help, but only if it maps to a real workflow. If the integration does not solve a live problem, it may not matter how modern the API looks.

This is why interoperability should be tied to business value. The best integrations remove friction, save staff time, or improve data flow in a visible way. If they do not, they can slow the deal instead of helping it.

How evidence and adoption break down

In short: Evidence and adoption fail for different reasons, but they often happen together.

Evidence and adoption fail for different reasons, but they often happen together. A product can have strong funding and still stall if the proof is too weak for the claims being made. A product can also have decent evidence but fail if people do not want to use it in daily life. Both problems matter.

The key is to match proof level to product promise. General support tools need one kind of evidence. Clinical products need another. The more serious the claim, the more serious the proof must be.

Do digital therapeutics need stronger proof?

Usually yes, especially if they claim clinical outcomes. Not every product needs a randomized trial at launch, but stronger claims do need stronger evidence over time. Enterprise buyers and payers will often ask for endpoints, not just testimonials.

This is where many teams overreach. If the sales deck sounds like a treatment claim, the proof needs to support that level of promise. Otherwise, the product may look credible in marketing but weak in procurement.

Are behavior change features failing to engage?

If users stop coming back after the first week or two, the engagement design may be off. Many teams copy streaks, reminders, and badges from consumer apps without testing whether those tools fit health use cases. In care settings, people often need support at specific moments, not constant prompts.

Good behavior design should match the user's real routine. It should reduce friction, not add pressure. If the feature set looks busy but the retention curve drops fast, that is an early signal that the product is not meeting users where they are.

Ready to turn insight into action?

Gray Group International works with business leaders to turn insight into action. Reading about the right approach is one thing; building the team, processes, and decisions that actually move metrics inside your specific organization is another. That second part is where most of the value lives, and it's where we focus.

Every engagement starts with a working session, not a deck. We listen to where you are today, look at the data and constraints with you, and propose the next two or three concrete moves that we believe will produce the most leverage. You leave with a plan you can act on whether or not you continue to work with us.

Let's Connect